ÖÊÆ×¼¼Êõ
È«°ÐÏò´úл×éѧ
´úл×éѧÊÇÕë¶Ôϸ°ûÄÚг´úл¹ý³ÌÖвúÉúµÄ·Ö×ÓÁ¿Ð¡ÓÚ1000µÀ¶û¶ÙµÄС·Ö×Ó²úÎï½øÐÐÈ«ÃæɸѡºÍ¼ì²âµÄѧ¿Æ¡£´«Í³µÄ´úл×éѧÑо¿²ßÂÔ£¬ÏÈͨ¹ý·Ç°ÐÏò´úл×éѧ¼¼Êõ½øÐй㷺ɸѡ£¬Ëø¶¨²îÒì´úлÎÔÙ½øÐÐÌض¨´úлÎïµÄ°ÐÏò´úл×éѧ¼ì²â·½·¨µÄ¿ª·¢£¬¼Ì¶øÍê³É´úл×éѧÑо¿¡£
·Ç°ÐÏò´úл×éѧ¼¼ÊõÒ»°ãÊÇͨ¹ýÖÊÆ×»ñÈ¡´úлÎïËéÁÑÀë×ÓÐÅÏ¢ºó£¬Ó빫¹²Êý¾Ý¿âÖеĴúлÎïËéÁÑÀë×ÓÖ±½Ó½øÐбȶԷÖÎö£¬½ø¶ø»ñÈ¡±¾µØ¼ì²âµÄ´úлС·Ö×ӵĶ¨ÐԺͶ¨Á¿ÐÅÏ¢¡£È»¶ø£¬ÓÉÓÚ´úлС·Ö×ӵķÖ×ÓÁ¿Ð¡£¬½á¹¹¼òµ¥£¬½ö½öÓ빫¹²Êý¾Ý¿â±È¶Ô¼ø¶¨µÄ½á¹û²¢²»¿É¿¿£¬Ö÷ÒªÔÒòÈ磺1. ¹«¹²Êý¾Ý¿âµÄÊý¾ÝÐÅÏ¢À´Ô´¸´ÔÓ£¬²»Í¬Êý¾Ý¿â±È¶ÔµÄÊý¾Ý´æÔÚÆ«²î£¨Èç×óͼ£©¡£2. ´úл·Ö×ÓÔÚ²»Í¬ÒÇÆ÷Éϳö·åʱ¼ä²¢²»Ïàͬ£¬Óñ¾µØÒÇÆ÷²É¼¯µÄÊý¾ÝºÜÄÑÍêÈ«Æ¥ÅäÊý¾Ý¿âÖеÄÒÇÆ÷³ö·åʱ¼ä£¬Ôì³É±È¶ÔÐÅϢƫ²î¡£ 3. С·Ö×ӽṹ¼òµ¥£¬ºÜÈÝÒ׳öÏÖͬ·ÖÒì¹¹Ì壬½ö½ö»ùÓÚËéÁÑÁ£×ӵıȶԣ¬ÄÑÒÔÇø·ÖС·Ö×Óͬ·ÖÒì¹¹Ìå¡£
| È«°ÐÏò´úлоƬ¼¼Êõ·Ïß
| ¼¼ÊõÓÅÊÆ
1. ¹ú¼Ê±ê×¼´úл×éѧ¼¼Êõ·Ïߣ¬¸ßͨÁ¿¾ø¶Ô¶¨Á¿¼ì²â300+ÖÖ¹¦ÄÜÐÔС·Ö×Ó´úлÎï
2. 300+ÖÖ±ê׼Ʒ²»Í¬ÏßÐÔ·¶Î§¶¨Á¿¸ßµÍŨ¶È´úлÎͬλËØÄÚ±êÒ»¶ÔһУÕý
3. ¹ã·ºº¸Ç̼ˮ»¯ºÏÎï¡¢ÓлúËá¡¢°±»ùËá¡¢¶ÌÁ´Ö¬·¾Ëá¡¢Öг¤Á´Ö¬·¾Ëá¡¢µ¨ÖËá¡¢ºËÜÕËáµÈ´úлÎïÀàȺ
4. Ñù±¾Ç°´¦ÀíºÍÑÜÉú»¯¾ùʵÏÖ»úе±Û×Ô¶¯»¯²Ù×÷£¬±ÜÃâÈ˹¤²Ù×÷Îó²îºÍ´úлÎïµÄµÈ´ý½µ½âÎÊÌâ
5. ΢Á¿µÎ¶¨°å¼ì²â£¬MRM¶àͨµÀͬʱ²É¼¯±£Áôʱ¼äºÍÀë×Ó¶ÔÐÅϢȷ±£´úлÎᆱ׼¼ø¶¨£»
6. ÊÊÓÃÓÚѪÇ塢Ѫ½¬¡¢×éÖ¯¡¢·à±ã¡¢³¦µÀÄÚÈÝÎϸ°û¡¢Ï¸°ûÅàÑøÒº¡¢ÍÙÒºµÈ¸÷ÖÖÉúÎïÑù±¾ºÍÎïÖÖ£¨¶¯Î¡£
| Ó¦ÓÃÁìÓò£º
1. ÉúÎï±êÖ¾ÎïÑо¿Óë·¢ÏÖ
2. ËÞÖ÷-³¦µÀ¾úȺ¹²´úлÑо¿
3. ¼²²¡¸¨ÖúÕï¶ÏÓëÔ¤·À
4. ÖÐÒ©ÏÖ´ú»¯Ñо¿
5. Ò©ÎïÑз¢¼°Ò©ÎïҩЧÆÀ¼Û
6. ÓªÑø¡¢Ô˶¯Ó뽡¿µ
| ÑùÆ·ÒªÇó
ÒѲâÑùÆ·£ºÑª£¨Ñª½¬¡¢ÑªÇ塢ȫѪ¡¢ÑªÆ¬µÈ£©¡¢×éÖ¯£¨¸Î¡¢³¦¡¢ÄÔ¡¢·Î¡¢Æ¤·ô¡¢Ì¥ÅÌ¡¢Ö¬·¾µÈ£©¡¢ÄòÒº¡¢³¦ÄÚÈÝÎï¡¢·à±ã¡¢ÍÙÒº¡¢¾«Òº¡¢ÂÑÅÝÒº¡¢ÈéÖ¡¢µ¨Ö¡¢Éà̦¡¢ÑòË®¡¢Ï¸°ûºÍϸ°ûÅàÑøÒº¡¢ÍâÃÚÌ塢΢ÉúÎïµÈ¡£
| ¿Í»§ÎÄÏ×
[1]. Shuai Menglei, Zhang Guoqing, Zeng Fang-Fang, et al. Human Gut Antibiotic Resistome and Progression of Diabetes. Adv Sci (Weinh), 2022, 9: e2104965. IF=16.806
[2]. Shuai Menglei, Fu Yuanqing, Zhong Hai-Li et al. Mapping the human gut mycobiome in middle-aged and elderly adults: multiomics insights and implications for host metabolic health. Gut, 2022, undefined. IF=23.059
[3]. Yanyu Jiang, Xi Yang, Changsheng Dong, et al, Five©\Day Water©\Only Fasting Decreased Metabolic©\Syndrome Risk Factors and Increased Anti©\Aging Biomarkers without Toxicity in a Clinical Trial of Normal©\Weight Individuals. Clin Transl Med. 2021 Aug;11(8):e502. IF=11.492
µØÖ·£ºÉϺ£ÊÐãÉÐÐÇøÂÌÖÞ»·Â·396Ū5´±4²ã
µç»°£º400-869-2936£¬021-33968791
ÓÊÏ䣺support@wayenbiotech.com
´«Õ棺021-33938792
QQ£º2120485725
Õ½ÂÔºÏ×÷
Õ½ÂÔºÏ×÷
| Full Moon | RayBiotech | CDI | IZON | Bio-Rad | R&D Systems | IsoPlexis | ÄÏÄ£ÉúÎï | Å·Ò×ÉúÎï | ÆäÃ÷ÐÅÏ¢ | ÃÀ¼ªÉúÎï | ÂóÌØ»æÆ× |
Ìرð˵Ã÷£º±¾ÍøËùÓÐÍøÒ³¾ùΪk8¿·¢(Öйú)Ô´´ÐÅÏ¢£¬×ªÔرØÐëÕ÷Çók8¿·¢(Öйú)ͬÒ⣬²¢Í¬Ê±×¢Ã÷±¾ÍøÃû³Æ¼°ÍøÖ·¡£